Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) EBITDA (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed EBITDA for 6 consecutive years, with -$23.9 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 35.01% to -$23.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$135.8 million through Dec 2025, down 0.74% year-over-year, with the annual reading at -$129.8 million for FY2025, 1.86% down from the prior year.
  • EBITDA for Q4 2025 was -$23.9 million at TScan Therapeutics, up from -$37.1 million in the prior quarter.
  • The five-year high for EBITDA was -$7.9 million in Q1 2021, with the low at -$38.7 million in Q2 2025.
  • Average EBITDA over 5 years is -$24.0 million, with a median of -$23.3 million recorded in 2023.
  • The sharpest move saw EBITDA crashed 120.92% in 2021, then surged 35.01% in 2025.
  • Over 5 years, EBITDA stood at -$14.2 million in 2021, then plummeted by 31.31% to -$18.6 million in 2022, then decreased by 14.52% to -$21.4 million in 2023, then tumbled by 71.9% to -$36.7 million in 2024, then soared by 35.01% to -$23.9 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$23.9 million, -$37.1 million, and -$38.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.